|Calculated MW||M=54,14 KDa|
|Antigen Region||401-495/495 aa|
|Other Names||Ectonucleoside triphosphate diphosphohydrolase 2, NTPDase 2, 361-, CD39 antigen-like 1, Ecto-ATP diphosphohydrolase 2, Ecto-ATPDase 2, Ecto-ATPase 2, ENTPD2, CD39L1|
|Format||0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce|
|Storage||Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃.|
|Function||In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Hydrolyzes ADP only to a marginal extent. The order of activity with different substrates is ATP > GTP > CTP = ITP > UTP >> ADP = UDP.|
|Cellular Location||Isoform Long: Cell membrane; Multi-pass membrane protein Isoform gamma: Endoplasmic reticulum membrane; Multi-pass membrane protein|
|Tissue Location||Brain, placenta, skeletal muscle, kidney, pancreas, heart, ovary, testis, colon, small intestine, prostate and pancreas. No expression in adult thymus, spleen, lung, liver and peripheral blood leukocytes|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. CD39L1 is a 495 amino acid multi-pass membrane protein that requires calcium and magnesium cofactors to hydrolyze ATP and other nucleotides in the regulation of purigenic neurotransmission. CD39L1 is expressed in kidney, colon, heart, testis, pancreas, brain, prostate, skeletal muscle, small intestine and ovaries. There are two isoforms of CD39L1 that are produced as a result of alternative splicing events.
Chadwick B.P.,et al.Mamm. Genome 8:668-672(1997).
Mateo J.,et al.Br. J. Pharmacol. 128:396-402(1999).
Mukasa T.,et al.Biochemistry 44:11160-11170(2005).
Humphray S.J.,et al.Nature 429:369-374(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.